Display Settings:

Format

Send to:

Choose Destination

    Hum Mol Genet. 2003 Oct 15;12(20):2625-35. Epub 2003 Aug 19.

    Alpha-synuclein degradation by serine protease neurosin: implication for pathogenesis of synucleinopathies.

    Iwata A, Maruyama M, Akagi T, Hashikawa T, Kanazawa I, Tsuji S, Nukina N.

    Laboratory for Structural Neuropathology, RIKEN Brain Science Institute, Saitama, Japan.

    Accumulation of insoluble alpha-synuclein aggregates in the brain is characteristic of Parkinson's disease, dementia with Lewy bodies and multiple system atrophy. Although numerous studies on the aggregation properties of alpha-synuclein have been reported, little is known about its degradation so far. In view of proteolytic degradation, we have found that the serine protease neurosin (kallikrein-6) degrades alpha-synuclein and co-localizes with pathological inclusions such as Lewy bodies and glial cytoplasmic inclusions. In vitro study showed that neurosin prevented alpha-synuclein polymerization by reducing the amount of monomer and also by generating fragmented alpha-synucleins that themselves inhibited the polymerization. Upon cellular stress, neurosin was released from mitochondria to the cytosol, which resulted in the increase of degraded alpha-synuclein species. Down-regulation of neurosin caused accumulation of alpha-synuclein within cultured cells. Thus we concluded that neurosin plays a significant role in physiological alpha-synuclein degradation and also in the pathogenesis of synucleinopathies.

    PMID: 12928483 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read